562. Multifocal Tuberculosis: The Revival of Interest
Session: Poster Abstract Session: Clinical Tuberculosis: Trends and Experiences
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • P 562.pdf (78.6 kB)
  • Background: Tuberculosis remains a major public health problem mainly in developing countries. The multifocal tuberculosis (MFT) has experienced resurgence since its prevalence keeps rising proportionally to the human immunodeficiency virus infection worldwide. We aim to compare the epidemiological, clinical characteristics between unifocal tuberculosis (UFT) and MFT and we intended to reveal involved prognosis factors.

    Methods: Through a retrospective study, we collected 332 patients hospitalized in the Department of Infectious Diseases between 1995 and 2013. They were divided into 2 groups: G1 with MFT (51 cases; 15.4%) and G2 with UFT (281 cases; 84.6%).

    Results: The mean age was similar between two groups (41.2±17 vs. 41.8±19 years; p=0.8). There were 32 females (62.7%) in G1 and 163 females (58%) in G2 (p=0.5). Rural background was more frequently listed in G1 (80.4% vs. 64.4% in G2; p=0.026). The diagnosis was confirmed mostly with histological findings (68% in G1 and 57.3% in G2; p=0.1). Mean hemoglobin and lymphocyte were significantly lower in G1 (10.2±3 vs. 11.9±3 g/dL; p<0.0001 and 1400±590 vs. 1700±821 E/mm3; p=0.02 respectively). Treatment-related side effects were more frequently encountered in G1 (49% vs. 33.8%; p=0.037 and OR=1.88). Hematological disorders were described in 7.8% in G1 and in 1.1% in G2 (p=0.02 and OR=7.88). The mean duration of in-hospital stay tended to be longer in G1 (21.3±19 vs. 16.4±16 days; p=0.06). Favorable outcome was more frequently found in G2 (80.4 vs. 94%; p=0.04). MFT was characterized by higher relapse (17.6 vs. 4.2%; p=0.002) and death rates (5.9 vs. 1.1%; p=0.04) (OR were 4.8 and 5.8 respectively).

    Conclusion: Our study drew attention to MFT as a severe form of tuberculosis, which is associated with higher morbidity and mortality. Therefore, we should be aware of poor prognosis factors in order to enhance survival of patients with MFT.

    Houda Ben Ayed, MD, Makram Koubaa, MD, Sahar Ben Kahla, MD, Asma Tlijani, MD, Chakib Marrakchi, MD, Boussaima Hammami, MD and Mounir Ben Jemaa, MD, Department of Infectious Diseases, Hedi Chaker University Hospital, Sfax, Tunisia

    Disclosures:

    H. Ben Ayed, None

    M. Koubaa, None

    S. Ben Kahla, None

    A. Tlijani, None

    C. Marrakchi, None

    B. Hammami, None

    M. Ben Jemaa, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.